Clinical Trial

A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well LY3549492 is tolerated and what side effects may occur in Japanese participants with Type 2 Diabetes Mellitus (T2D) and healthy Japanese participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3549492 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 19 weeks for both Part A (Cohorts 1-3) for multiple-ascending doses (MAD), and Part B (Cohorts 4-5) multiple-ascending doses (MAD), for a total of approximately 25 weeks, including screening.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-03-10; most recent amendment 2026-03-19.
Status change: Active, Not Recruiting → Completed 2026-03-19
Status change: Recruiting → Active, Not Recruiting 2025-11-17
Status change: Not Yet Recruiting → Recruiting 2025-05-28
Trial Details
NCT Number NCT06869018
Lead Sponsor Eli Lilly and Company
Conditions Healthy, Type 2 Diabetes Mellitus (T2D)
Enrollment 92 participants
Start Date 2025-05-07
Primary Completion 2026-03-02 (estimated)
Study Completion 2026-03-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-20